Crosstown rivals Novartis ($NVS) and Roche ($RHHBY) will be neck and neck for the No. 1 spot in pharma sales till 2022, with Roche ahead by a nose at the finish line, according to a new market analysis. Along the way, a 6.3% annual growth rate industrywide will take global prescription drug sales past the $1 trillion mark.
{iframe}http://www.fiercepharma.com/pharma/roche-to-topple-novartis-for-top-prescription-sales-by-2022-as-industry-threats-loom-report{/iframe}